Alcon’s Clareon Vivity IOL gains CE Mark approval, expanding vision correction options in Europe
Discover how Alcon’s Clareon Vivity IOL is transforming cataract surgery with CE Mark approval, offering presbyopia correction and extended vision clarity in Europe. Read More
Cipla secures exclusive rights to market Formosa Pharmaceuticals’ APP13007 across 11 countries
Cipla Limited has expanded its presence in the ophthalmology market through a multi-regional licensing agreement with Formosa Pharmaceuticals, granting it exclusive rights to commercialize APP13007, ... Read More
Diabetic retinopathy: How diabetes can lead to vision loss and what you can do about it
Diabetic retinopathy is a serious and potentially blinding complication of diabetes that affects the retina—the part of the eye responsible for processing light. Over time, ... Read More
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire EyeBio Limited, a prominent ... Read More
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have ... Read More
Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the ... Read More
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This ... Read More
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
OcuTerra Therapeutics moves forward with OTT166 eye drops in Phase 2 trial
OcuTerra Therapeutics, a clinical-stage ophthalmology company, announced the successful full enrollment in its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial. The trial ... Read More
Top North Georgia eye clinics merge to form North Georgia Eye Associates
Gainesville Eye Associates and North Georgia Eye Clinic, two of the major ophthalmology practices in North Georgia, have combined their operations to form North Georgia ... Read More